BACKGROUND: In a previous phase I clinical trial of dietary methionine (MET) restriction with cystemustine treatment for melanoma or glioma, we determined the optimal MET-free diet duration to be 1 day. On this basis, a phase II clinical trial was initiated to evaluate safety and efficacy of this combination. PATIENTS AND METHODS: Twenty-two patients (20 with metastatic melanoma and 2 with recurrent gloma) received a median of 4 cycles of the association of a 1-day MET-free diet with cystemustine (60 mg/m(2)) every two weeks. RESULTS: This association was well tolerated (toxicity and nutritional status). Toxicity remained mainly hematological and consisted of WHO grade 3-4 thrombocytopenia, leucopenia and neutropenia in 36, 27 and 27% of patients respectively. The median disease-free survival was 1.8 months and the median survival was 4.6 months, with 2 long-duration stabilizations. The plasmatic MET depletion obtained was of 40 + or - 31%.
BACKGROUND: In a previous phase I clinical trial of dietary methionine (MET) restriction with cystemustine treatment for melanoma or glioma, we determined the optimal MET-free diet duration to be 1 day. On this basis, a phase II clinical trial was initiated to evaluate safety and efficacy of this combination. PATIENTS AND METHODS: Twenty-two patients (20 with metastatic melanoma and 2 with recurrent gloma) received a median of 4 cycles of the association of a 1-day MET-free diet with cystemustine (60 mg/m(2)) every two weeks. RESULTS: This association was well tolerated (toxicity and nutritional status). Toxicity remained mainly hematological and consisted of WHO grade 3-4 thrombocytopenia, leucopenia and neutropenia in 36, 27 and 27% of patients respectively. The median disease-free survival was 1.8 months and the median survival was 4.6 months, with 2 long-duration stabilizations. The plasmatic MET depletion obtained was of 40 + or - 31%.
Authors: Deyang Yu; Shany E Yang; Blake R Miller; Jaclyn A Wisinski; Dawn S Sherman; Jacqueline A Brinkman; Jay L Tomasiewicz; Nicole E Cummings; Michelle E Kimple; Vincent L Cryns; Dudley W Lamming Journal: FASEB J Date: 2018-01-30 Impact factor: 5.191
Authors: Claudio Vernieri; Stefano Casola; Marco Foiani; Filippo Pietrantonio; Filippo de Braud; Valter Longo Journal: Cancer Discov Date: 2016-11-21 Impact factor: 39.397
Authors: Dmitry Malin; Yoonkyu Lee; Olga Chepikova; Elena Strekalova; Alexis Carlson; Vincent L Cryns Journal: Breast Cancer Res Treat Date: 2021-09-22 Impact factor: 4.872
Authors: Isabelle R Miousse; Julia Tobacyk; Charles M Quick; Azemat Jamshidi-Parsian; Charles M Skinner; Rajshekhar Kore; Stepan B Melnyk; Kristy R Kutanzi; Fen Xia; Robert J Griffin; Igor Koturbash Journal: Carcinogenesis Date: 2020-05-14 Impact factor: 4.741